This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT.
SparkCures ID | 1276 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 27 Patients |
Treatments | |
Tags |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Select Inclusion Criteria:
Select Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersLearn more about how we work with trial sponsors